These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 21559811)
21. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Hoelzer D; Gökbuget N Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S214-21. PubMed ID: 19778844 [TBL] [Abstract][Full Text] [Related]
22. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A; J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980 [TBL] [Abstract][Full Text] [Related]
25. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia]. Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049 [TBL] [Abstract][Full Text] [Related]
26. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Reman O; Pigneux A; Huguet F; Vey N; Delannoy A; Fegueux N; de Botton S; Stamatoullas A; Tournilhac O; Buzyn A; Charrin C; Boucheix C; Gabert J; Lhéritier V; Vernant JP; Fière D; Dombret H; Thomas X; Leuk Res; 2008 Nov; 32(11):1741-50. PubMed ID: 18508120 [TBL] [Abstract][Full Text] [Related]
27. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E; Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036 [TBL] [Abstract][Full Text] [Related]
32. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899 [TBL] [Abstract][Full Text] [Related]
33. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V; Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352 [TBL] [Abstract][Full Text] [Related]
34. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia]. Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462 [TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341 [TBL] [Abstract][Full Text] [Related]
36. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD; Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099 [TBL] [Abstract][Full Text] [Related]
37. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993 [TBL] [Abstract][Full Text] [Related]
38. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324 [TBL] [Abstract][Full Text] [Related]
39. [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia]. Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Chen H; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):31-4. PubMed ID: 15946506 [TBL] [Abstract][Full Text] [Related]
40. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]